Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00

By Dr. Matthew Watson

Orphazyme A/S har afholdt ordinær generalforsamling den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende dagsorden:

View original post here:
Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00

Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
Financière de Tubize - Dividend approval - April 28th, 2024
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B... - April 10th, 2024
Ultimovacs – Invitation to Business Update on April 17, 2024 - April 10th, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective... - April 10th, 2024
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - April 10th, 2024
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - April 10th, 2024
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today - April 10th, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - April 10th, 2024
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - April 10th, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious... - April 10th, 2024
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - April 10th, 2024
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference - April 10th, 2024
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2... - April 10th, 2024
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting - April 10th, 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - April 10th, 2024
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300... - April 10th, 2024
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual... - April 10th, 2024
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting - April 10th, 2024
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - April 10th, 2024
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients... - April 10th, 2024
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 - April 10th, 2024
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal... - March 26th, 2024
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - March 26th, 2024
Gedeon Richter Selects Trial Interactive for Clinical Trial Management - March 26th, 2024
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of... - March 26th, 2024
OXURION announces its presence at the Paris SmallCap event on March 28, 2024. - March 26th, 2024
Foreløbige tal for 2023 og finansielle forventninger til 2024 - March 26th, 2024
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 26th, 2024
Praxis Precision Medicines to Host PRAX-628 Program Update - March 26th, 2024
BioCryst to Present at Upcoming Investor Conferences - March 26th, 2024
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference - March 26th, 2024
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results - March 26th, 2024
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system - March 26th, 2024
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights - March 26th, 2024
Agile Therapeutics Announces Delisting from Nasdaq - March 26th, 2024
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - March 26th, 2024
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA... - March 26th, 2024
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - March 26th, 2024
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion - March 26th, 2024
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - March 26th, 2024
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - March 26th, 2024
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024

Global News Feed commento

Comments Off | data

April 19th, 2024

About... Dr. Matthew Watson

This author published 5492 posts in this site.

Comments are closed.

Previous post - Next post

Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites